Impact of Chronic Obstructive Pulmonary Diseases on Outcomes and Hospital Days After Percutaneous Coronary Intervention

Jian Wei Zhang(Capital Medical University), Xiao Xu(Capital Medical University), Qing Yang(Guangzhou University of Chinese Medicine), Bin Nie(Capital Medical University), Yu Jie Zhou(Capital Medical University), Shi Wei Yang(Capital Medical University)
Angiology
August 31, 2012
10.1177/0003319712458145
Cited by 14

Related Papers

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus
|Immunity|2016|378
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
|Clinical Cancer Research|2018|218
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
|British Journal of Cancer|2018|156
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
|Science Translational Medicine|2019|138